Countering Atherosclerosis in the Clinical Arena in 2020. Mechanistic and Therapeutic Advancements in Chronic Kidney Disease
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Nephrology & Urology".
Deadline for manuscript submissions: closed (31 July 2021) | Viewed by 2088
Special Issue Editor
Interests: CKD; ESRD; cardiovascular risk; atherosclerosis; endothelial dysfunction; drugs; treatment; nutrition
Special Issue Information
Dear Colleagues,
On a world scale over 850 million individual are affected by chronic kidney disease (CKD) making this condition an absolute public health priority. CKD associates with a very high risk for accelerated atherosclerosis and cardiovascular disease and the prognosis in these patients is notoriously poor. Diabetes and hypertension are rampant in CKD but risk for atherosclerotic complications in CKD goes far beyond traditional risk factors in this condition. Endothelial dysfunction, inflammation and oxidative stress, disturbed regulation of the renin-angiotensin system, alterations in the lipid profile, prothrombotic factors and a unique propensity for vascular calcification all compound the high risk scenario of CKD.
Statins and new drugs like sodium-glucose transport protein 2 (SGLT2) inhibitors and non-steroidal antagonists of the mineralocorticoid receptor reduce cardiovascular risk in patients with moderate CKD. Bromodomain and Extra-Terminal domain proteins (BET) form a class of epigenetic readers that trigger genes implicated in inflammation, oxidative stress and vascular calcification thereby accelerating atherosclerosis. Emerging evidence suggests that the inhibition of these proteins may bring cardiovascular benefits in high risk conditions like CKD.
Countering atherosclerosis in CKD patients is a priority. Research in this area attracts an ever increasing number of investigators. Progress in the understanding of risk factors implicated in cardiovascular disease in this population may bring benefits going even beyond this condition.
Prof. Dr. Carmine Zoccali
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- CKD
- ESRD
- Cardiovascular risk
- Atherosclerosis
- Endothelial dysfunction
- Drugs
- Treatment
- Nutrition
